Kenvue Inc.$19.51TKO · NYSE
Consensus is Buy across 11 analysts, with a mean target of $229. The supplied consensus does not report low or high targets, so target clustering and spread cannot be measured, and it names no individual analysts; consequently, the most and least bullish firms cannot be identified. No analyst rating or target revisions are explicitly reported during the week. The substantive evidence-based disagreement is between the Q2 revenue beat and raised full-year 2026 revenue and adjusted EBITDA outlook, versus the 17.79% earnings miss. The +0.71% revenue surprise suggests the debate concerns earnings conversion and outlook credibility rather than demand alone. No detailed target dispersion or analyst rationale is supplied.
